PGPIPN
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
PGPIPN is a milk-derived hexapeptide — not a skincare peptide. It came through the same source directory as the rest of this cosmetic-topical peptide family, but doesn’t actually belong to the cosmetic-skincare story; it’s documented here only for completeness, with an honest “this isn’t what it looks like” note.
What does it do in my body?
The public profile (graded Emerging, 3 studies, 0 human) describes preclinical anti-cancer and immune-modulation work: inhibiting ovarian-cancer cell invasion and growth in vitro and in vivo via MTA1/NM23H1 and BCL2 pathways.
How can it help me?
- Where the science stands: Emerging: 3 preclinical studies, 0 human
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No adverse-effect data was captured in the source profile beyond the preclinical anti-cancer/immune-modulation research context. Safety is graded pending, not the “green” default of the genuinely topical-cosmetic members of this cluster.
Regulatory status: Not a cosmetic ingredient. This is a preclinical research compound, not FDA-reviewed and not sold through cosmetic or peptide-vendor channels per the captured source material.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
No topical or cosmetic use case exists for PGPIPN. No dosing or protocol information relevant to a skincare/cosmetic context was captured in the source material.
What should I avoid combining — and what's synergistic?
PGPIPN doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
Not actually a skincare peptide — a milk-derived hexapeptide from preclinical anti-cancer research that landed in a cosmetic directory by category drift. Documented here for completeness, with the same honest “this isn’t what it looks like” note the source material gives it.
| Class | Not a topical cosmetic peptide — a milk-derived research compound, mis-filed into the cosmetic-peptide directory |
| Mechanism (one line) | Preclinical: inhibits ovarian-cancer cell invasion and growth in vitro and in vivo via MTA1/NM23H1 and BCL2 pathways |
| Evidence base | Emerging: 3 preclinical studies, 0 human |
| Safety record | Safety: pending |
| Regulatory status | Research compound, not a cosmetic ingredient and not FDA-reviewed |
What it is
PGPIPN is a milk-derived hexapeptide — not a skincare peptide. It came through the same source directory as the rest of this cosmetic-topical peptide family, but doesn’t actually belong to the cosmetic-skincare story; it’s documented here only for completeness, with an honest “this isn’t what it looks like” note.
How it works
The public profile (graded Emerging, 3 studies, 0 human) describes preclinical anti-cancer and immune-modulation work: inhibiting ovarian-cancer cell invasion and growth in vitro and in vivo via MTA1/NM23H1 and BCL2 pathways.
What the research shows
Graded Emerging on the public profile: 3 preclinical studies, 0 human trials, describing ovarian-cancer cell-invasion inhibition via the MTA1/NM23H1 and BCL2 pathways.
OHM’s internal 0035 categorization pass grades PGPIPN Tier D / pending / provisional with a SECONDARY heal-recover label and “minimal published human data”.
Status: an immune/oncology research peptide that landed in a cosmetic list by category drift — included here only so the cluster migration is complete. This is not skincare content and should not be treated as one.
Real-world protocol
No topical or cosmetic use case exists for PGPIPN. No dosing or protocol information relevant to a skincare/cosmetic context was captured in the source material.
Side effects & management
No adverse-effect data was captured in the source profile beyond the preclinical anti-cancer/immune-modulation research context. Safety is graded pending, not the “green” default of the genuinely topical-cosmetic members of this cluster.
Regulatory status
Not a cosmetic ingredient. This is a preclinical research compound, not FDA-reviewed and not sold through cosmetic or peptide-vendor channels per the captured source material.
Sources
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Emerging, 3 preclinical studies, 0 human. Describes MTA1/NM23H1 and BCL2 pathway ovarian-cancer research.
- OHM tier/safety grading: Tier D / pending / provisional, SECONDARY heal-recover, “minimal published human data.”
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration — the source explicitly flags this compound as miscategorized into the cosmetic directory.
Sources & references
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Emerging, 3 preclinical studies, 0 human. Describes MTA1/NM23H1 and BCL2 pathway ovarian-cancer research.
- OHM tier/safety grading: Tier D / pending / provisional, SECONDARY heal-recover, “minimal published human data.”
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration — the source explicitly flags this compound as miscategorized into the cosmetic directory.